Safety aspects and rational use of a naproxen + esomeprazole combination in the treatment of rheumatoid disease

por Roberts, David N, Miner, Philip B
Publicado 2011

Influence of Demographic Factors on Clinical Outcomes in Adults With Chronic Idiopathic Constipation Treated With Plecanatide

por Rao, Satish S.C., Laitman, Adam P., Miner, Philip B.
Publicado 2023

Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study

por Miner, Philip B, Silberg, Debra G, Ruth, Magnus, Miller, Frank, Pandolfino, John
Publicado 2014

Exploring the physiologic role of human gastroesophageal reflux by analyzing time‐series data from 24‐h gastric and esophageal pH recordings

por Lu, Luo, Mu, John C., Sloan, Sheldon, Miner, Philip B., Gardner, Jerry D.
Publicado 2014

Long-Term Safety and Effectiveness of Lubiprostone, a Chloride Channel (ClC-2) Activator, in Patients with Chronic Idiopathic Constipation

por Lembo, Anthony J., Johanson, John F., Parkman, Henry P., Rao, Satish S., Miner, Philip B., Ueno, Ryuji
Publicado 2011

Pilot, Randomized, Blinded, Placebo-Controlled Trial Investigating the Correlation Between Acid Control and Heartburn Relief with 14 Days of Esomeprazole Treatment

por Miner, Philip B., Johnson, David A., Katz, Philip O., Li, Jing, Gatoulis, Sergio C., Pollack, Charles
Publicado 2018

Time esophageal pH < 4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors

por Gerson, Lauren B, Triadafilopoulos, George, Sahbaie, Peyman, Young, Winston, Sloan, Sheldon, Robinson, Malcolm, Miner, Philip B, Gardner, Jerry D
Publicado 2008